Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 8.08 +0.26 (3.33%)
Day High: 8.23
Day Low:  7.76
Volume:    444,602
4:00 PM ET
Mar 23, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

Mar 13, 2017 / 11:00 AM ET